Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo

New insights into the pathophysiology of dyslipidemia in type 2 diabetes

(2015) Marja-Riitta Taskinen et al.   ATHEROSCLEROSIS

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

(2015) Christopher P. Cannon et al.   EUROPEAN HEART JOURNAL

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

PCSK9

(2014) Nabil G. Seidah et al.   CIRCULATION RESEARCH

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial

(2014) Eli M. Roth et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

National Lipid Association Annual Summary of Clinical Lipidology 2015

(2014) Harold E. Bays et al.   Journal of Clinical Lipidology

Very Large Database of Lipids: Rationale and Design

(2013) Seth S. Martin et al.   CLINICAL CARDIOLOGY

Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile

(2013) Seth S. Martin et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Friedewald-Estimated Versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications

(2013) Seth S. Martin et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction

(2012) Anders Berg Jørgensen et al.   EUROPEAN HEART JOURNAL

Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

(2012) James M. McKenney et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease

(2012) Anette Varbo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

(2012) Evan A Stein et al.   LANCET

A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease

(2012) Anastazia A. Kei et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia

(2012) Eli M. Roth et al.   NEW ENGLAND JOURNAL OF MEDICINE

ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

(2011) et al.   EUROPEAN HEART JOURNAL

Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists

(2011) Michael H. Davidson et al.   Journal of Clinical Lipidology

Lipoprotein subfractions and cardiovascular disease risk

(2010) Ronald M Krauss   CURRENT OPINION IN LIPIDOLOGY

Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?

(2010) Harold Bays et al.   Lipids in Health and Disease

LDL Receptor-Related Protein 1: Unique Tissue-Specific Functions Revealed by Selective Gene Knockout Studies

(2008) Anna P. Lillis et al.   PHYSIOLOGICAL REVIEWS